Acarix

Acarix Current Liabilities

The Current Liabilities of Acarix (ACARIX.ST) as of Nov 12, 2026 is 10.16 M SEK. In the previous year, Current Liabilities was 5.06 M SEK — a change of 100.61% (higher).

Current Liabilities

10.16 MSEK

YoY

100.61%

Last updated:

Current Liabilities of Acarix is 2025 10.16 M SEK. Current Liabilities of Acarix was 2024 5.06 M SEK. It decreases by 100.61% higher compared to the previous year.

The Acarix Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
7.32 M SEK
Jan 1, 2019
10.84 M SEK
Jan 1, 2020
12.84 M SEK
Jan 1, 2021
18.10 M SEK
Jan 1, 2022
17.91 M SEK
Jan 1, 2023
11.00 M SEK
Jan 1, 2024
5.06 M SEK
Jan 1, 2025
10.16 M SEK
The Acarix Current Liabilities history
YEARCurrent LiabilitiesYoY
10.16 MSEK+100.61%
5.06 MSEK-53.96%
11.00 MSEK-38.58%
17.91 MSEK-1.08%
18.10 MSEK+40.98%
12.84 MSEK+18.47%
10.84 MSEK+48.05%
7.32 MSEK+43.05%
5.12 MSEK-71.20%
17.77 MSEK+416.12%
3.44 MSEK+8.92%
3.16 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

Current Liabilities of Acarix is 10.16 M SEK in 2025.

Current Liabilities of Acarix changed from 5.06 M SEK to 10.16 M SEK, representing a 100.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Acarix since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Acarix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acarix

All Key Metrics — Acarix